LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Gesloten

3.06 13.75

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.7800000000000002

Max

3.22

Belangrijke statistieken
By Trading Economics
Inkomsten	672K -877K
EPS	-0.24
Winstmarge	-60,266.667
Werknemers	2
EBITDA	671K -877K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-9M 8.9M
Vorige openingsprijs	-10.69
Vorige sluitingsprijs	3.06

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb 2026, 22:36 UTC

Winsten

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb 2026, 22:32 UTC

Winsten

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb 2026, 23:58 UTC

Marktinformatie

Winsten

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb 2026, 23:58 UTC

Marktinformatie

Winsten

Global Energy Roundup: Market Talk

23 feb 2026, 23:47 UTC

Marktinformatie

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb 2026, 23:43 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb 2026, 23:40 UTC

Marktinformatie

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb 2026, 23:40 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb 2026, 23:39 UTC

Acquisities, Fusies, Overnames

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb 2026, 23:31 UTC

Winsten

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb 2026, 23:31 UTC

Winsten

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb 2026, 23:28 UTC

Winsten

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb 2026, 23:27 UTC

Winsten

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb 2026, 23:24 UTC

Marktinformatie

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb 2026, 22:31 UTC

Winsten

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 22:24 UTC

Winsten

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb 2026, 22:22 UTC

Winsten

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb 2026, 22:21 UTC

Winsten

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb 2026, 22:21 UTC

Winsten

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb 2026, 22:20 UTC

Winsten

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.